Trial reportThe Journal of rheumatology2011
Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Trial report in The Journal of rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study
Precision Medicine in Systemic Sclerosis Gastrointestinal Disease: Evaluating Imaging and Stool Biomarkers for Differentiating Disease Stages and Treatment Responses
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The role of prokinetics in managing gastrointestinal involvement in SSc: a systematic literature review.Rheumatology (Oxford, England) · 2025Pooled it
- Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.Rheumatology (Oxford, England) · 2015Pooled it
- Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database.The American journal of gastroenterology · 2014Pooled it
- Transcutaneous auricular branch vagal nerve stimulation as a non-invasive add-on therapeutic approach for pain in systemic sclerosis.RMD open · 2023Trial
- Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.PloS one · 2020Trial
- Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.Arthritis research & therapy · 2017Trial
- Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.Best practice & research. Clinical rheumatology · 2026Review
- Gastrointestinal Symptoms in Systemic Sclerosis: Prevalence and Severity across Disease Subtypes and Autoantibody Profiles.Acta medica Lituanica · 2026Article
- Prevalence, clinical characteristics, and hospital course of systemic sclerosis-associated pseudo-obstruction.Clinical rheumatology · 2025Article
- Observational
- Characteristics of patients with systemic sclerosis with aspiration: A single-center study.Journal of scleroderma and related disorders · 2025Article
- Meaningful differences in patient-reported outcome measurement scores in liver disease.Hepatology communications · 2025Article
- Systemic sclerosis-related fecal incontinence: a scoping review focusing on a neglected manifestation.Rheumatology (Oxford, England) · 2025Article
- Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?RMD open · 2024Article
- Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study.BMJ open · 2024Article
- Determinants of Six-Minute Walk Test Performance in Women with Systemic Sclerosis.Journal of musculoskeletal & neuronal interactions · 2023Article
- The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.Clinical and experimental rheumatology · 2023Article
- Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.International journal of environmental research and public health · 2023Article
- Gastrointestinal symptom severity and progression in systemic sclerosis.Rheumatology (Oxford, England) · 2022Article
- Management of scleroderma gastrointestinal disease: Lights and shadows.Journal of scleroderma and related disorders · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo provide minimally important difference (MID) estimates for the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) in a longitudinal observational cohort.
methodsWe administered the UCLA SCTC GIT 2.0 to 115 patients with systemic sclerosis (SSc) at 2 timepoints 6 months apart. The UCLA SCTC GIT 2.0 has 7 multi-item scales: Reflux, Distension/Bloating, Diarrhea, Fecal Soilage, Constipation, Emotional Well-being, and Social Functioning and a total GIT score. All scales are scored from 0 [better health-related quality of life (HRQOL)] to 3 (worse HRQOL) except the diarrhea and constipation scales (ranges 0-2 and 0-2.5, respectively). Patients also rated their overall and upper and lower GIT involvement during the second visit using a response scale with options "much better; somewhat better; almost the same; somewhat worse; or much worse." The minimally changed group was defined by those reporting they were somewhat better or somewhat worse compared to first visit.
resultsStudy participants were 84% female and 81% white with a mean disease duration of 6.9 years. The MID estimates for improvement ranged from 0.07 for the Social Functioning scale to 0.36 for the Emotional Well-being scale. For worsening, the MID estimates ranged from 0.06 for the Fecal Soilage scale to 0.21 for the Social Functioning scale.
conclusionWe provide MID estimates for the UCLA SCTC GIT 2.0 scales. This information can aid in interpreting scale scores in future randomized controlled trials and observational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.